Optimize Cell Line Development for First-in-Human Success:
Building Better Clones

An efficient transition from drug discovery to first-in-human studies requires highly productive clones with the right product quality, scalable processes and rapid process development toward robust GMP manufacturing. Establishing effective cell line development strategies early can help address challenges related to productivity, expression stability and product quality throughout biologics development.

This webinar explores how advances in cell line development, including targeted gene integration, stable pool generation and automated clone screening, can support the selection of producer clones for downstream development and manufacturing.

Gene integration strategies that use transposase-mediated, epigenetically targeted integration direct genes to the most transcriptionally active genomic sites. This can yield bulk pools with high, stable titers and consistent product quality, which can be used early to produce material for early development activities and toxicology studies. Establishing productivity and expression stability early can also allow clone screening efforts to place greater emphasis on product quality and process performance.

Assessing product quality across large numbers of clones remains a critical challenge, and addressing it early opens the door to better clone selection. Automated screening enables earlier evaluation of large clone panels for productivity, upstream process compatibility and critical quality attributes. Combined with advanced product characterization, this can deliver high-quality producer clones in a shorter timeframe, supporting scalable manufacturing and rapid progression towards first-in-human studies.

Register for this webinar to learn how advanced cell line development and smart clone selection can help pave the path to scalable manufacturing and successful first-in-human studies.